Evidence Hub

Severe Hypertriglyceridemia Managed in a Pregnant Patient Using Nonstatin Therapies

Roy R, Altenberg M, Faulkner S, Dickens L, Horan M, Davidson M, Patel H

JACC. Case reports, 2026

Abstract

Background: Severe hypertriglyceridemia (HTG) in pregnancy is associated with increased maternal-fetal morbidity. Treatment options remain limited because of fetal safety concerns.

Case summary: A 34-year-old pregnant patient with type 2 diabetes mellitus and HTG was referred to our cardio-obstetrics multidisciplinary team for management of HTG at 16 weeks of gestation. She was managed with omega-3 acid ethyl esters, insulin, and lifestyle modifications, with improvement in levels noted over 4 months.

Discussion: This case highlights the complexities of managing severe HTG in pregnancy. Although many lipid-lowering agents are avoided during pregnancy, high-risk women with concurrent type 2diabetes mellitus may be treated with insulin and omega-3 fatty ethyl esters.

Take-home messages: Severe HTG in pregnancy is associated with increased risk of maternal-fetal morbidity. Management of severe HTG in pregnancy includes preconception risk assessment, multidisciplinary care, intensive lifestyle modification, selective use of nonstatin agents, and monitoring throughout and after pregnancy.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free